Erlotinib Completed Phase 1 Trials for Unspecified Adult Solid Tumor, Protocol Specific / Recurrent Bladder Cancer / Stage IIIb Non-small Cell Lung Cancer / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Untreated Metastatic Squamous Neck Cancer With Occult Primary / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Adult Diffuse Astrocytoma / Adult Oligodendroglioma / Stage IV Rectal Cancer / Adult Anaplastic Ependymoma / Recurrent Basal Cell Carcinoma of the Lip / Adult Glioblastoma / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Stage IV Esophageal Cancer / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Anal Cancer / Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Adult Primary Liver Cancer / Recurrent Salivary Gland Cancer / Recurrent Colon Cancer / Recurrent Lymphoepithelioma of the Nasopharynx / Stage II Pancreatic Cancer / Male Breast Cancer / Adult Giant Cell Glioblastoma / Recurrent Lymphoepithelioma of the Oropharynx / Stage II Esophageal Cancer / Stage IVB Cervical Cancer / Advanced Adult Primary Liver Cancer / Stage IV Lymphoepithelioma of the Nasopharynx / Adult Primary Hepatocellular Carcinoma / Adult Mixed Glioma / Recurrent Verrucous Carcinoma of the Larynx / Stage IV Lymphoepithelioma of the Oropharynx / Recurrent Adult Brain Tumor / Advanced Malignant Mesothelioma / Stage IV Salivary Gland Cancer / Adult Subependymoma / Adult Myxopapillary Ependymoma / Adult Pilocytic Astrocytoma / Recurrent Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Larynx / Metastatic Bladder Cancer / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Basal Cell Carcinoma of the Lip / Recurrent Rectal Cancer / Recurrent Malignant Mesothelioma / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage III Pancreatic Cancer / Stage IV Anal Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Cervical Cancer / Recurrent Prostate Cancer / Stage IV Squamous Cell Carcinoma of the Oropharynx / Metastatic Colon Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage III Esophageal Cancer / Recurrent Esophageal Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Breast Cancer / Stage IV Verrucous Carcinoma of the Oral Cavity / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Adult Brain Stem Glioma / Adult Ependymoblastoma / Recurrent Pancreatic Cancer / Adult Gliosarcoma / Adult Anaplastic Astrocytoma / Stage IV Non-Small Cell Lung Cancer / Recurrent Cervical Cancer / Stage IV Pancreatic Cancer / Recurrent Squamous Cell Carcinoma of the Oropharynx / Stage IV Prostate Cancer / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Larynx / Non-Small Cell Lung Cancer Recurrent / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Breast Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Adult Anaplastic Oligodendroglioma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00030498Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00088959Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT01839955Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer
NCT00042809Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors
NCT00126620Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00276575Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
NCT00320073Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors